Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00483990 · ClinicalTrials.gov registry record · Phase 1

Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers

A Phase 1 study of Healthy, sponsored by Plethora Solutions.

Completed
Registry status
Phase 1
Development phase
16
Enrollment target
1
Study location

NCT00483990: Completed Phase 1 study of Healthy, sponsored by Plethora Solutions.

NCT00483990 is a Phase 1 study of Healthy that has completed, run by Plethora Solutions. The registered enrollment target is 16 participants, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00483990, a Phase 1 study of Healthy, has completed, sponsored by Plethora Solutions.

COMPLETED
Registry status
Phase 1
Development phase
16 participants
Enrollment target
1
Study location

Study Summary

The main objective of the study is to determine the safety and tolerability of repeated application of PSD502 to the glans penis in healthy male volunteers

Conditions Studied

Interventions

  • DRUG PSD502

Study Locations (1)

Kansas

  • PRA International - Clinical Pharmacology Center - Lenexa

Trial Details

FieldValue
Enrollment Target 16 participants
Start Date 2007-03
Est. Completion 2007-06
Phase Phase 1

Sponsor

Plethora Solutions

3 total trials

What the Registry Record Tells You About NCT00483990

The ClinicalTrials.gov registry entry for NCT00483990 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 647-participant average among 1,090 other Healthy trials with a reported enrollment target (98% lower). The listed sponsor is Plethora Solutions, which has 3 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Healthy appearing as the primary indexed condition, and to 1 intervention - of which PSD502 is the first listed.

NCT00483990 reports 1 study location spanning 1 distinct geographic area - top geographies include Kansas.

Frequently Asked Questions

What is clinical trial NCT00483990 about?

NCT00483990 is a clinical study titled "Phase I Study of PSD502 (Lidocaine Prilocaine Spray) Applied to the Glans Penis up to Three Times a Day for 21 Days in Healthy Male Volunteers". The main objective of the study is to determine the safety and tolerability of repeated application of PSD502 to the glans penis in healthy male volunteers

What is the current status of trial NCT00483990?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2007-03. Estimated completion is 2007-06.

What conditions does trial NCT00483990 study?

This clinical trial studies the following conditions: Healthy.

What interventions are being tested in trial NCT00483990?

The interventions under investigation include: PSD502 (DRUG).

Who is sponsoring clinical trial NCT00483990?

This trial is sponsored by Plethora Solutions, which has 3 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00483990 being conducted?

This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Healthy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.